Page 7 - Liminal Bioscience News Today

Equities research analysts predict that Liminal BioSciences Inc. (NASDAQ:LMNL – Get Rating) will post earnings per share of ($0.16) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Liminal BioSciences’ earnings. Liminal BioSciences posted earnings of ($0.52) per share in the same quarter last year, which indicates a […]

Planned Phase 1a Single Ascending Dose ("SAD") clinical trial, commencing in Q2 2022, to compare fezagepras with sodiumphenylbutyrate as a nitrogen scavenger Repayment in full of the $39.1M

/PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), today reported its financial results for the fourth quarter...

/PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), today reported its financial results for the fourth quarter...

/PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), today provides an update on plans for the further development...

Liminal BioSciences Provides Update on Its Lead Drug Candidate Fezagepras Analysis of PK data from Phase 1 Multi-Ascending Dose clinical trial completed ... | March 14, 2022

/PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), announced today that on March 4, 2022, it received a written...

LAVAL, QC, and CAMBRIDGE, ENGLAND, March 7, 2022 /PRNewswire/ -- Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), announced today that on March 4, 2022, it received

/PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), announced today that on March 4, 2022, it received a written...

Repayment eliminates total debt of $39.1M Early Repayment results in: Total interest savings of CA$9.1MImmediate termination of Loan Agreement and release of security interests over all